Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226561 | 0.90 | ALDH1A1 (0.52) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL17827812 | 0.90 | GLO1 (0.56) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL4661645 | 0.90 | ALDH1A1 (0.52) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL16305056 | 0.87 | GLO1 (0.45) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL2357523 | 0.83 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL10886996 | 0.83 | ALDH1A1 (0.46) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL3678281 | 0.83 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL14194445 | 0.83 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL3678277 | 0.83 | GLO1 (0.50) | GLO1ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL28265003 | 0.82 | GLO1 (0.45) | GLO1ALDH1A1LMNAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240158405-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4121167-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605267-A | Selective modulators of mutant LRRK2 proteolysis and related methods of use | 阿维纳斯企业公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220064168-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-03-03 | — | — | US | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-5958948-A | CORTICOTROPIN RELEASING FACTOR; THERAPY FOR STRESS | PFIZER, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5705646-A | Substituted pyrazoles as CRF antagonists | PFIZER INC. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0764153-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5514821-A | SKIN DISORDERS; MEDIATORS OF CELL GROWTH AND DIFFERENTIATION | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995033727-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0674631-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013661-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-4410721-A | Process for the preparation of cyclopropene intermediates | ROUSSEL UCLAF (FR) | 1983-10-18 | — | — | US | disclosed |
| US-4299973-A | Alkyl 3,3-dimethyl-2-(2-hydroxy-2-methyl-propyl)-1-cyclopropene-1-carboxylates | ROUSSEL UCLAF (FR) | 1981-11-10 | — | — | US | disclosed |
| US-4028278-A | Cycloaliphatic unsaturated ketones as fragrance modifying agents | FIRMENICH S.A. (CH) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | GLO1 1891/4885ALDH1A1 1895/4885LMNA 2116/4885 |
| US-20240158405-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | LRRK2, ADRM1, CRBN | GLO1 1458/4885ALDH1A1 4021/4885LMNA 2534/4885 |
| US-20220064168-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | LRRK2, ADRM1, CRBN | GLO1 1458/4885ALDH1A1 4021/4885LMNA 2534/4885 |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | GLO1 1458/4885ALDH1A1 4021/4885LMNA 2534/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | GLO1 1458/4885ALDH1A1 4021/4885LMNA 2534/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | GLO1 4600/4885ALDH1A1 4659/4885LMNA 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.